[Follow-up study on anti-HBs levels in vaccines after two and three doses of HB vaccine (1)].
An HB prophylaxis vaccination that included a primary and secondary vaccination was carried out on persons working at this university hospital. In the primary vaccination, the subjects were inoculated the second time with a vaccine derived from human blood plasma obtained from the Kitazato Therapeutic Research Institute. The third time, they were inoculated with a vaccine from the Chemo-Sero Therapeutic Research Institute derived from a second-generation vaccine organized ferment. The vaccine used for the second inoculation was obtained from the Chemo-Sero Therapeutic Research Institute.


RESULTS
A total of 254 subjects were inoculated with the HB prophylaxis vaccination. 1. Of the 216 subjects inoculated with the primary vaccination, at the time of the second inoculation, 65 subjects (30%) tested positive for antibodies 3-4 months following inoculation. There was an especially high rate among females between 20 and 50 years. Thirty-two subjects (15%) tested positive 15-16 months following inoculation with a high rate among females. 2. Among 132 subjects inoculated the third time with the primary vaccination (those who tested negative in the second inoculation of the above vaccine), 76 subjects (58%) tested positive for antibodies 8-9 months following inoculation with a generally high rate among females. Thirty-five subjects (27%) tested positive 15-16 months after inoculation with a high rate among females between 20 and 30 years and among males between 40 and 60 years. 3. Among the 38 subjects who were inoculated the second time with the secondary vaccination, 8 subjects (21%) tested positive for antibodies 5 months following inoculation, with a high rate among females in their 20's.
Kimura
T
T
Department of Clinical Pathology and Clinical Laboratories, Kanagawa Dental College.
Iwamiya
M
M
Yoshida
N
N
Iwamoto
A
A
Sasada
M
M
Ito
S
S
Kikuchi
N
N
Yagi
S
S
Shikone
M
M
Higaki
M
M
D000328:Adult; D005260:Female; D005500:Follow-Up Studies; D006509:Hepatitis B / Q000276:immunology / Q000517:prevention & control*; D006510:Hepatitis B Antibodies / Q000097:blood*; D006801:Humans; D008297:Male; D008875:Middle Aged; D014611:Vaccination; D014761:Viral Hepatitis Vaccines / Q000008:administration & dosage*
D006510:Hepatitis B Antibodies; D014761:Viral Hepatitis Vaccines